Velsera

Velsera is a global precision medicine technology company that accelerates the discovery, development, and delivery of precision medicine through integrated AI-enhanced software and expert services. With over a decade of innovation and industry firsts, Velsera partners with life sciences and clinical diagnostic companies to provide cutting-edge technology that helps them bring new drugs and diagnostics to market faster — combating genetic diseases such as cancer and improving patient outcomes worldwide.

Velsera serves a broad range of customers including biotech and pharma companies, clinical diagnostic laboratories, NGS assay and equipment manufacturers, non-profits, and government agencies. The company supports 7 of the top 10 global pharma companies, has more than 18,000 researchers using its Seven Bridges Platform, supports over 80 active clinical NGS lab customers, has processed more than 250,000 NGS samples, and maintains connections to data representing over 175 million patients across 50+ data partners.

Integrated Solutions Portfolio

• Velsera Global Data Network: Provides access to millions of patient records to accelerate precision medicine research and drug development at scale, offering real-world, longitudinal clinicogenomic data to pharma and biotech organizations.
• Clinical & Multi-omic Data Access: Harmonizes and augments multimodal datasets to unlock the value within clinical and omics data sources.
• Analysis & Bioinformatics: Delivers cutting-edge technology — including the Seven Bridges Platform — to enable new discoveries and accelerate breakthroughs in research and drug development.
• Companion Diagnostic Development & Scaling: Supports the development of better diagnostics that scale faster, accelerating the uptake of novel drugs.
• NGS Assay Development & Expansion: Helps customers bring new tests to market quickly, with over 20 productized NGS assays available off the shelf and year-over-year sequencing volume growth exceeding 20%.
• IVD Compliance Transition: Guides organizations through the changing regulatory environment to ensure effective navigation and growth under IVD compliance requirements.
• Clinical Interpretation & Reporting: Accelerates the scale-up of genetic testing and unlocks the value in clinical genomics data through streamlined reporting workflows.

Key Platforms and Products

• Seven Bridges Platform: A multi-cloud bioinformatics platform used by over 18,000 researchers globally, supporting large-scale omics analytics, graph-based genomic approaches, and complex transcriptomics data analysis for drug discovery and research workflows.
• Clinical Genomics Workspace (CGW): An integrated software solution for clinical NGS laboratories that streamlines sequencing data analysis and clinical report generation, reducing logistical burden and improving reporting uniformity. Trusted by institutions such as Weill Cornell Medicine and Dartmouth-Hitchcock Health.
• RHEO: An automated bioinformatics solution designed to bring precision and flow to bioinformatics pipeline execution.

Core Capabilities

• AI-enhanced software for multimodal data analysis spanning genomics, transcriptomics, and other omics data types.
• IVD validation support and regulatory compliance services for clinical laboratories and assay manufacturers.
• Expert bioinformatics and cloud computing services leveraging multi-cloud infrastructure.
• Clinicogenomic data harmonization and augmentation to support both research and clinical decision-making.
• End-to-end support from early drug discovery through companion diagnostic development and clinical-scale NGS reporting.

Customers, Reach, and Industry Position

• Recognized as one of the largest omics analytics providers in the market.
• Technology supports 7 of the top 10 global pharmaceutical companies.
• Powers the knowledgebase behind Illumina's TSO Comprehensive Test, approved in Japan.
• Trusted by leading academic medical centers including Weill Cornell Medicine and Dartmouth-Hitchcock Health.
• Serves biotech, pharma, clinical diagnostic labs, NGS manufacturers, non-profits, and government agencies globally.
• Maintains a network of 50+ data partners providing access to data representing over 175 million patients.

Leadership and Company Background

• Velsera has a track record of over 10 years of innovation in precision medicine, combining established scale with continued agility and a mission-driven culture.
• The executive team includes leaders with deep experience from organizations such as Foundation Medicine, IBM Life Sciences, McKinsey & Company, Optum, and Sema4.
• Key leaders include CEO Jamie Coffin, CTO Mike Kling, Chief Strategy and Product Officer Pavel Gongora, and General Managers overseeing the Seven Bridges, CGW, and Global Data Network business units.
• The company's core belief is that the slow pace of precision medicine advancement stems from siloed data, information, and expertise — and that connecting these assets can drive a step-change in global health outcomes.

Velsera's integrated approach — combining a powerful global data network, advanced bioinformatics platforms, clinical NGS reporting tools, and expert services — positions it as a comprehensive partner for organizations seeking to accelerate every stage of the precision medicine journey, from early discovery through clinical diagnostics and patient care.